Overview

Atorvastatin for HAART Suboptimal Responders

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:
0

Participant gender:
All

Summary

We hypothesise that atorvastatin changes immune activation among HAART-treated adults with suboptimal cluster cell differentiation 4 (CD4) recovery by 25%

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Makerere University

Collaborator:

Vaccine and Gene Therapy Institute, Florida

Treatments:

Atorvastatin
Atorvastatin Calcium

Criteria

List of inclusion Criteria: HIV-infected adults on antiretroviral therapy for at least 6
years with sustained viral suppression (viral load<400 copies), and CD4 increase below 300
cells (difference between current and baseline CD4 count).

List of exclusion Criteria: History of an opportunistic infection within the previous six
months, Pregnancy, History of myositis, History of ingestion of lipid-lowering agents at
the baseline visit, Use of therapeutic agents known to have substantial drug-drug
interactions with statins, and individuals on PI-containing HAART